Insights

The European Medicines Agency has recently started a phased review for a medicine intended to treat metastatic pancreatic cancer, with the aim of accelerating the assessment of a product that may address a high unmet medical need. Under this approach, available data can be assessed in stages before the submission of a complete Marketing Authorisation Application (MAA).

This development reflects a broader regulatory trend in Europe: creating more flexible, science-driven and patient-focused assessment pathways for promising medicines. It also aligns with the ongoing reform of the EU pharmaceutical framework, which aims to support innovation, improve patient access and reduce unnecessary procedural complexity.

For pharmaceutical companies developing innovative products, phased review may represent an important opportunity. Earlier assessment of selected data packages could help streamline the regulatory process and potentially shorten the time between clinical evidence generation and regulatory decision-making.

However, accelerated pathways also require strong preparation. Companies must ensure that clinical, quality and non-clinical data are sufficiently mature, consistent and aligned with regulatory expectations. Submitting data earlier does not reduce the need for scientific robustness, a well-supported benefit-risk rationale and a clear overall dossier strategy.

A phased review approach may also have significant operational implications. Regulatory, Clinical Development, CMC, Pharmacovigilance, Medical writing and Market Access functions must work in close coordination to ensure that each data package is submission-ready at the appropriate time, that responses to authority questions can be managed efficiently, and that evidence generation plans support both regulatory decision-making and future access requirements.

Although this pathway may remain limited to selected high-priority medicines, it signals an important evolution in the European regulatory environment. For companies developing products in areas of high unmet medical need, early regulatory planning, cross-functional alignment, dossier readiness and considerations of future market access requirements are becoming increasingly important success factors.

Regulatory Pharma Net (RPN) supports pharmaceutical and biotech companies through multidisciplinary teams working across Regulatory Affairs, Clinical Development, CMC, Pharmacovigilance, Medical Writing and Market Access, helping companies build robust development, evidence generation and submission strategies for innovative products.

From early regulatory planning and dossier readiness assessments to agency interactions, submission strategy development and cross-functional strategic planning, RPN provides the integrated expertise needed to maximise preparedness for accelerated assessment opportunities and evolving EU regulatory and market access pathways.